P. Goeminne (Bornem, Belgium), F. Ringshausen (Hannover, Germany), M. Loebinger (London, United Kingdom), A. Dimakou (Agia Paraskeyi, Greece)
Phenotype characterization of non-cystic fibrosis bronchiectasis in India. R. Dhar (Kolkata (West Bengal), India)
| |
PROGNOSIS - the German Bronchiectasis Registry: first results F. Ringshausen (Hannover, Germany)
| |
The effect of gender on sputum microbiological profile in non-cystic fibrosis bronchiectasis K. Lee (London, United Kingdom)
| |
Non-cystic fibrosis bronchiectasis: etiology and predictors of exacerbations and mortality in patients across the largest health system in central and western Massachusetts J. Lee (Providence, United States of America)
| |
Neutrophil extracellular trap formation in peripheral blood and airway neutrophils in bronchiectasis and CF R. Keir (Dundee, United Kingdom)
| |
Open label case-control study to assess Pidotimod efficacy in Non CF Bronchiectasis Disease: a pilot study M. D'Amato (Napoli, Na, Italy)
| |
Aetiology of non-CF bronchiectasis in adults and its association to quality of life L. Terpstra (Alkmaar, Netherlands)
| |
Chronic lobe collapse: another bronchiectasis phenotype or a marker of Pseudomonas colonisation? O. Munteanu (Chisihau, Republic of Moldova)
| |
The pulmonary microbiome in non-cystic fibrosis bronchiectasis. M. Mac Aogáin (Singapore, Singapore)
| |
RISK FACTORS FOR ISOLATION MULTIDRUG-RESISTANT PATHOGENS IN BRONCHIECTASIS EXACERBATIONS E. Amara Elori (VALENCIA, Spain)
| |
High frequencies of Aspergillus colonization and associated inflammation in stable bronchiectasis M. Mac Aogáin (Singapore, Singapore)
| |
Bronchospasm secondary to nebulised antibiotics in bronchiectasis R. Njafuh (SOUTHSEA, United Kingdom)
| |
Adherence in bronchiectasis (BQ) and concordance between multidimensional scales in a cohort of patients colonized by Pseudomonas aeruginosa (PsA). E. Garcia Cortacero (Granada, Spain)
| |
Chest physiotherapy in European patients with bronchiectasis: Data from the EMBARC registry B. Herrero Cortina (Zaragoza, Spain)
| |
Non-tuberculous mycobacteria – number of drugs and duration of treatment – does it matter? J. Ibrahim (Walsall, United Kingdom)
| |
The efficacy, safety and feasibility of inhaled amikacin for the treatment of refractory non-tuberculous mycobacterial lung diseases K. Yagi (Tokyo, Japan)
| |
Five year Cohort Analysis of Non-Tuberculosis Mycobacterium Lung Disease at a Tertiary Referral Centre H. Kunst (London, United Kingdom)
| |
Long-term Outcome of Pulmonary Resection for Nontuberculous Mycobacterial Pulmonary Disease T. Asakura (Tokyo, Japan)
| |
Aspergillus precipitating antibody in patients with Mycobacterium avium complex lung disease; cross-sectional study S. Suzuki (Tokyo, Japan)
| |
Non Tuberculous Mycobacteria in Calabria region: a retrospective cross-sectional study. L. SURACE (Italy)
| |